Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Open-label phase 1b trial. Study treatment will be administered in 3 week cycles. There are two distinct parts in this study: * Part 1: Dose escalation from IMO-2055 * Part 2: Once a recommended phase 2 dose is found additional tolerability and pharmacodynamics will be explored
创建时间：
2009-01-15
